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2+, 3+. States: A feature selection is executed by a modeler who decides which set 
of features describes a disease state or patient cohort best. For identifying the most 
relevant attribute combinations a cluster analysis is applied beforehand. Transitions: 
Patients remain in one particular state as long as they match the predetermined 
features and attributes. Otherwise, a change to another state occurs. Thereby, a 
sequence of states for each patient is defined. As a final step, these sequences are 
used for deriving a model structure. ExpEctEd REsults: Markov models backed up 
by real-life patient records. As a result of the automatic generation process models 
can be used for validating hypotheses or comparing outcomes for different patient 
cohorts. Therefore, the usage of such models is not strictly limited to health eco-
nomic analysis. A first validation indicates the feasibility of the outlined methods. 
It was possible to reconstruct a published disease model. conclusions: Ongoing 
research is conducted with focus on data quality, i.e., accuracy, completeness and 
timeliness, at the regional cancer registry.
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objEctivEs: A 10-step, systematic framework to enhance patient engagement 
throughout the CER process has been previously proposed. The objective of this 
research was to apply this framework in the context of CVD since CVD is the 
leading cause of death in the United States and impacts a diverse patient popu-
lation. MEthods: At each of the 10 steps in the research process, the rationale 
and means for researchers to engage CVD patients is presented. REsults: When 
prioritizing CER topics, patients can inform whether resources should be allocated 
towards hypertension, a highly prevalent disease with various established thera-
peutic options, or into finding new treatment options for patients affected by pul-
monary arterial hypertension, a rare disease. Patients with CVD can also help to 
select outcomes that are meaningful from their perspective. Interest in the major 
outcomes (stroke, heart failure) will likely be balanced against patient concerns 
with treatment side effects, such as dizziness and dry cough, which can impact 
quality of life. In the latter steps of translation and dissemination, patients can 
help to tailor results under primary, secondary, or tertiary prevention and across 
racial/ethnic subgroups. conclusions: The 10-step framework can be tailored 
to engage patients with CVD. For some stages of CER, purposes and strategies for 
patient engagement for CVD are similar to many other disease states. However, 
there are unique best practices for patient engagement in CVD. Researchers should 
recognize that there is no “one-size-fits-all” approach to patient engagement and 
should engage CVD patients throughout the CER continuum.
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objEctivEs: In rare diseases and sub-populations for specialty diseases, national 
and regional payer negotiations regarding funding and reimbursement of new 
drugs can be challenging due to the lack of available robust data to inform deci-
sion making. Clinical trials designed to ensure regulatory approval often lack the 
necessary information to meet the needs of a diverse range of payer and clinical 
stakeholders across the globe. Traditional patient registries, if available, generally 
do not capture the required level of detail, especially in terms of health-economic 
data. To ensure ongoing access, new therapies to treat rare diseases require further 
real world evidence to build a strong clinical and economic case for long term 
treatment provision. MEthod: We employed a variety of traditional and innova-
tive methods to collect real-world evidence on disparate populations of patients 
with rare diseases. Retrospective chart review studies have been conducted to 
understand demographics, clinical and pathological characteristics, treatment, 
outcomes and resource use. Patient and caregiver surveys have subsequently been 
used to correlate quality of life, functional status and economic burden to patient 
treatment pathways. REsults: Non-interventional studies provided a longitudi-
nal understanding of patient care pathway from diagnosis to long-term treatment 
and follow-up including the natural history of a rare disease, genotypic/phenotypic 
variability, differences in treatment patterns across countries and the clinical drivers 
of therapy use. This enabled comparison of real-world treatment practice versus 
clinical guidelines. In addition, direct and indirect costs were calculated to under-
stand the budget impact of treatment. Insights helped the manufacturer refine the 
product value proposition and provide necessary evidence to support product access 
and reimbursement. conclusions: Rare disease non-interventional studies offer 
manufacturers the opportunity to fulfill peri and post-launch evidence needs of 
regulators and payers by providing bespoke and robust real world data efficiently.
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Since 2004, DECIT supports the production of SR by teaching and research institu-
tions in Brazil. However, these studies were guided by international recommenda-
tions causing some variability in the execution and presentation of results. In order 
to standardize and equalize the elaboration quality of SRs throughout Brazil, DECIT 
requested to research institute Hospital do Coração Hcor draft this guideline. The 
initiative was funded by the Support Program for the Institutional Development of 
the Brazilian Public Health System. The guideline was based on two international 
and truncating the analysis. REsults: The survival outcomes produced by the 
model are presented graphically to illustrate the impact of the different methods, 
along with the magnitude of change in the incremental benefits and the resulting 
incremental cost-effectiveness ratios (ICERs) using the various methods compared 
to the standard approach. Conclusion: Capturing and quantifying the structural 
uncertainty in partitioned survival analysis is not well developed in the literature. 
This study demonstrates the considerable uncertainty and the potential for bias 
from choosing one method of extrapolating outcomes for an economic evaluation 
using a partitioned survival analysis. The study also proposes options for exploring 
the uncertainty in order to present a balanced analysis and avoid bias in economic 
evaluations for oncology research.
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intRoduction: PRO measures aimed at child respondents are generally devel-
oped with the input of children from the target population, although in certain 
cases their age or medical condition can have implications that make this less 
feasible. This extends also to the translation and linguistic validation of these 
measures, where the usual standard of pilot testing translations with the target 
population may not be appropriate or beneficial. This presentation investigates 
the challenges of pilot testing translations with children, and explores alternative 
validation methods. bAckgRound: Current guidelines advise that translated PRO 
measures should be tested with patients from the target population to best assess 
the measures’ suitability. From our own findings, pilot testing with children can 
be very successful as they give more creative answers during cognitive interviews, 
and they can be more willing to give open, honest answers than adults. However, 
the success of pilot testing with children can vary depending on their age. Younger 
children may have too limited a vocabulary to express concepts in their own words, 
or may struggle to understand the cognitive debriefing process. Additionally, in 
some circumstances there may be ethical issues involved when asking ill children 
to decide whether to participate in this process which may be difficult for them to 
understand. AltERnAtivEs: Alternative methods must aim to establish the same 
information that would be obtained from the target population: i.e., whether the 
translation is appropriate for that group. Therefore we propose review processes 
involving parents, teachers, paediatric nurses or clinicians, depending on the meas-
ure’s content and target age range. conclusion: In some cases it is possible to 
successfully pilot test translated PRO measures with children, and it can be the 
optimum solution, where practical. However, reviews by parents or suitably quali-
fied professionals are useful alternatives where testing with children might not 
be feasible.
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In many diseases, the occurrence of a clinical event (e.g., stroke) can change the 
risk of other, usually more serious, events (e.g., death). Quantifying the impact of 
the first event and factoring this into assessment or extrapolation of the risk of the 
second event is important for clinical understanding of the disease as well as health 
economic assessments of new treatments. For instance, in oncology, understanding 
the impact of progression of disease on the risk of dying can be vital for projection of 
overall survival, which is often only partially observed in trials. Proper understand-
ing of the impact of the event requires consideration of not only the occurrence of 
the event, but also its timing and the possibility that its effect changes with time 
following the event. For instance, patients who progress early after initiation of 
treatment may be subject to a greater increase in risk of death than a patient who 
progresses, say, a year after treatment. Similarly, once progressed, the increase in 
mortality may be highest soon after the event and gradually decline among surviv-
ing patients. We will outline a statistical modeling framework designed to quantify 
these various dimensions of the impact of events using Cox regression models 
with time-dependent covariates and effects (i.e., coefficients) to reflect the timing 
of event (TE) as well as time elapsed since the event (TSE). The model produces 
estimates that have direct clinical relevance; for instance, the coefficient for TE 
provides an assessment of the benefit of delaying progression, while TSE reflects 
whether and for how long the increase in mortality is sustained and whether it 
ever returns to the level of patients who had not progressed. The parameterization 
of the model will be illustrated with example code and analyses of example data.
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objEctivEs: Health economic disease models are often build with data from clinical 
trials and thus do not necessarily reflect the routine care situation in hospitals. For 
this scenario, we outline a method to generate disease models using data mining 
algorithms on patient records from a regional clinical cancer registry. MEthods: 
Markov models are a common technique in decision making. Their structure of 
states and transitions reflects the progress of a disease. We define a disease state as 
a set of features which represents a specific state of illness, e.g., diagnosis of breast 
cancer in HER-2-positive (human epidermal growth factor receptor 2) women who 
are treated with chemotherapy and mastectomy. In particular, a feature can consist 
of several attributes, e.g., HER-2 status can be described with the attributes 0, 1+, 
